Chinese programme 2021

Language session
Chairs: J. Qu (Shanghai, China), N. Roche (Paris, France)
Aims: To present and discuss the new advances in respiratory medicine presented by experienced speakers from the European Respiratory Society leadership and Chinese leaders in respiratory medicine; to present an overview of hot respiratory disease topics in Europe and China.

Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies: a longitudinal, population-level, cross-sectional study in Wuhan, China C. Wang (Beijing, China)
Long-COVID: What will be the legacy from the pandemic? C. Brightling (Leicester (Leicestershire), United Kingdom)
The role of epithelium-dependent fibroblast activation in pulmonary fibrosis W. Ning (Tianjin, China)
Interstitial lung diseases and COVID-19: myths and reality K. Antoniou (Heraklion, Greece)
Radiomics in lung cancer: progress and challenges W. Li (Chengdu (Sichuan), China)
Winners and losers:  Managing chronic respiratory patients during the COVID-19 pandemic J. Chorostowska-Wynimko (Warsaw, Poland)
Discussion and Q&A